key: cord-0923795-o3cfolip
authors: Lee, Yu-Lin; Liao, Chia-Hung; Liu, Po-Yu; Cheng, Chien-Yu; Chung, Ming-Yi; Liu, Chun-Eng; Chang, Sui-Yuan; Hsueh, Po-Ren
title: Dynamics of anti-SARS-Cov-2 IgM and IgG antibodies among COVID-19 patients
date: 2020-04-23
journal: J Infect
DOI: 10.1016/j.jinf.2020.04.019
sha: b7cbc2b5024e99b85614cddbfd9e139ea99c4b45
doc_id: 923795
cord_uid: o3cfolip

nan

Wang et al in this Journal recently reported a COVID-19 patient with prolonged viral shedding even after seroconversion. 1 The patient's antibody to SARS-CoV-2 viral nucleocapsid (N) protein, as determined by western blotting using infected cell lysates, was firstly identified on the tenth day after symptom onset. However, detection of antibody to SARS-CoV-2 by western blot is time-consuming, labor-intensive, and expertise-dependent.

Furthermore, data on antibodies to SARS-CoV-2 IgM or IgG were lacking.

Fourteen COVID-19 patients who were treated at six hospitals in Taiwan between January and March 2020 were enrolled in this study. The patients were classified into two groups: symptomatic and asymptomatic/mild symptoms. Patients designated in the symptomatic group had a fever for more than 3 days, obvious pneumonia patches on chest radiographs, and respiratory distress defined as oxygen saturation less than 95% or needing oxygen supply during hospitalization. Patients who did not meet the criteria of the symptomatic group were included in the asymptomatic/mild symptom group.

Samples from the respiratory tract for SARS-CoV-2 rRT-PCR testing included oropharyngeal and nasopharyngeal swabs, oral gargling, and sputum. All samples were submitted to virology laboratories validated and contracted by the Centers for Diseases Control and Prevention in Taiwan for testing. 2 Three sets of primers and probes targeting SARS-COV-2 envelope (E), nucleocapsid (N), and RNA-dependent RNA polymerase (RdRp) genes were used. In addition to SARS-CoV-2 RT-PCR testing, all respiratory samples were simultaneously evaluated for the presence of Influenza A/B viruses using RT-PCR.

When the results were negative for both SARS-CoV-2 and Influenza A/B viruses, an additional SARS-CoV-2 rRT-PCR test for another respiratory sample from the suspected COVID patient was performed.

The frequencies of antibody testing of the 14 COVID-19 patients were performed at the discretion of the attending physicians at each participating hospital. Anti-SARS-CoV-2 IgM and IgG antibodies in 33 serum samples collected from the 14 COVID-19 patients were determined using the ALLTEST 2019-nCoV IgG/IgM Rapid Test Cassette (Hangzhou ALLTEST Biotech Co., Ltd. Hangzhou, China). 2, 3 In addition, 28 control serum samples collected from 28 hospitalized patients (illness days 7-14), with respiratory tract infection but two negative results of SARS-CoV-2 rRT-PCR testing, were also evaluated to validate the performance of the assay. Among the 28 samples, three were known to be positive for either Table 1 . Age distribution of patients in both groups was similar, but more males tended to belong to the asymptomatic/mild symptom group. All patients in the symptomatic group acquired SARS-CoV-2 from abroad, including four in Wuhan, one in Macau, and one who had contact during their trip to Europe with a sick patient from Wuhan.

Half of the patients in the asymptomatic/mild symptom group were infected locally in Taiwan, without any travel history. A few patients had underlying co-morbid diseases; one had diabetes mellitus and followed diet control, and another had HIV infection and was undergoing treatment with anti-retroviral agents (regimens not including protease inhibitor).

All patients in the symptomatic group had fever, but only one patient in the asymptomatic/mild symptom group had fever.

Patients in the symptomatic group had higher proportions of abnormal laboratory data and data from imaging studies than those in the asymptomatic/mild symptom group (Table 1) .

Consequently, there were more patients in the symptomatic group prescribed with antibacterial agents, anti-viral agents, and even hydroxychloroquine. Eleven patients were discharged from the hospitals under relatively stable conditions, while three were still hospitalized. None of the patients developed respiratory failure and a need for ventilator support during hospitalization. Moreover, there were no mortalities observed in this study.

Of the six patients in the symptomatic group, all had positive anti-SARS-CoV-2 IgG and four had positive anti-SARS-CoV-2 IgM responses (Fig. 1A) . The duration of positive rRT-PCR results ranged from 12 to 46 days. Patients with positive anti-SARS-CoV-2 IgM results seemed to have a short duration of viral shedding (Fig. 1A) . For the eight patients in the asymptomatic/mild symptom group, none had positive anti-SARS-CoV-2 IgM results and three (cases 11-13) had negative anti-SARS-CoV-2 IgG results (Fig. 1B) . The last day of anti-SARS-CoV-2 IgM/IgG testing after the notification of positive rRT-PCR for these three cases was >42 days in case 11, >28 days in case 12, and 13 days in case 13. In case 13, a 30-yearold man was tested with rRT-PCR assay for SARS-CoV-2 due to travel exposure but did not 

The authors declare no conflict of interest. 

Prolonged virus shedding even after seroconversion in a patient with COVID-19

A case of COVID-19 and pneumonia returning from Macau in Taiwan: Clinical course and anti-SARS-CoV-2 IgG dynamic

Package Insert. ALLTEST 2019-nCoV IgG/IgM Rapid Test Cassette

Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis

Featuring COVID-19 cases via screening symptomatic patients with epidemiologic link during flu season in a medical center of central Taiwan

Neutralizing antibodies in patients with severe acute respiratory syndrome-associated coronavirus infection

Convalescent plasma as a potential therapy for COVID-19

The role of phylogenetic analysis in clarifying the infection source of a COVID-19 patient